Acquisitions and Other Transactions (Tables)

3 Months Ended

Mar. 31, 2016

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

As of March 31, 2016, the preliminary allocation of the $711.1 million purchase price to the assets acquired and liabilities assumed for Jai Pharma Limited is as follows:



(In millions)	Preliminary Purchase Price Allocation as of November 20, 2015 ^(a)			Measurement Period Adjustments ^(b)			Preliminary Purchase Price Allocation as of March 31, 2016 (as adjusted)
Current assets (excluding inventories)	$	25.7		$	—		$	25.7
Inventories	4.9			—			4.9
Property, plant and equipment	17.2			—			17.2
Identified intangible assets	437.0			—			437.0
In-process research and development	98.0			—			98.0
Goodwill	317.2			8.1			325.3
Other assets	0.7			—			0.7
Total assets acquired	900.7			8.1			908.8
Current liabilities	(9.1		)	(1.9		)	(11.0		)
Deferred tax liabilities	(180.5		)	(6.2		)	(186.7		)
Net assets acquired	$	711.1		$	—		$	711.1

____________


^(a)	As previously reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as amended.


^(b)	The measurement period adjustments are related to the recognition of certain current liabilities and adjustments to deferred tax liabilities to reflect facts and circumstances that existed as of the acquisition date.

EPD Business

Business Acquisition [Line Items]

Pro forma information for the EPD Transaction

Unaudited Pro Forma Financial Results

The following table presents supplemental unaudited pro forma information as if the acquisition of the EPD Business had occurred on January 1, 2014. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable, or have been achieved, subsequent to the EPD Transaction Closing Date. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisition been completed on January 1, 2014, nor are they indicative of the future operating results of Mylan N.V.



	Three Months Ended
	March 31,
(Unaudited, in millions, except per share amounts)	2015
Total revenues	$	2,118.7
Net earnings attributable to Mylan N.V. ordinary shareholders	$	76.9
Earnings per ordinary share attributable to Mylan N.V. ordinary shareholders:
Basic	$	0.16
Diluted	$	0.15
Weighted average ordinary shares outstanding:
Basic	491.3
Diluted	517.1